Healthcare · Biotechnology
Price
$0.95
Market Cap
$2.0M
Employees
13
Beta
1.15
Avg Volume
487,393
CEO
Peter O'Heeron
Business Description
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Business History
Price Overview
Last updated: Jun 30, 2026 9:34pm (just now)$0.95
+0.15 (+19.22%)
Day Range
$0.80 – $0.95
52-Week Range
$0.73 – $14.68
50-Day MA
$1.11
200-Day MA
$5.19
Volume
262,228.00
Analyst Price Targets
Low
$180.00
Consensus
$180.00
High
$180.00
(1 analysts)
Share Structure
Outstanding
2,095,972.00
Float
1,603,307.00
Free Float
76.5%
Normal free float
— 76.5% of shares trade freely, ~23.5% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (1.6M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.11
Stock Price: $0.95
EPS (Diluted): -8.40
EPS (Diluted): -8.40
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.63
Stock Price: $0.95
Total Equity: $6.16M
Shares: 2,233,026
Total Equity: $6.16M
Shares: 2,233,026
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.17
Market Cap: $1.99M
Total Debt: $0.00
Cash: $4.89M
EBITDA: -$17.61M
Total Debt: $0.00
Cash: $4.89M
EBITDA: -$17.61M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$7.6M
Market Cap: $1.99M
Total Debt: $0.00
Cash: $4.89M
Total Debt: $0.00
Cash: $4.89M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $0.95
Revenue: $0.00
Shares: 2,233,026
Revenue: $0.00
Shares: 2,233,026
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$832,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$16.65M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$18.65M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-767.1%
Net Income: -$18.65M
Total Equity: $6.16M
Total Equity: $6.16M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-338.4%
Operating Income: -$16.65M
Tax Rate: 0.0%
Equity: $6.16M
Total Debt: $0.00
Cash: $4.89M
Tax Rate: 0.0%
Equity: $6.16M
Total Debt: $0.00
Cash: $4.89M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.61
Current Assets: $6.35M
Current Liabilities: $1.76M
Current Liabilities: $1.76M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $6.16M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $6.16M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 2,233,026
Shares: 2,233,026
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.76
Total Equity: $6.16M
Shares: 2,233,026
Shares: 2,233,026
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-7.46
Operating CF: -$16.39M
CapEx: -$262,000
Shares: 2,233,026
CapEx: -$262,000
Shares: 2,233,026
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.95
Stock Price: $0.95
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$18.65M
Net Income: -$18.65M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares FBLG against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 30, 2026 9:34pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $832,000 |
| Gross Profit | $0 | $0 | $0 | $0 | $-832,000 |
| Operating Expenses | $1.6M | $4.5M | $8.9M | $13.7M | $15.8M |
| Operating Income | -$1.6M | -$4.5M | -$8.9M | -$13.7M | -$16.6M |
| Net Income | -$1.6M | -$5.1M | -$16.5M | -$11.2M | -$18.6M |
| EBITDA | -$1.6M | -$4.4M | -$15.9M | -$10.6M | -$17.6M |
| EPS | $-0.97 | $-3.20 | $-11.80 | $-6.80 | $-8.40 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 30, 2026 9:34pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $407,000 | $2.3M | $9.2M | $14.0M | $4.9M |
| Total Current Assets | $468,000 | $2.6M | $9.2M | $14.2M | $6.3M |
| Total Assets | $468,000 | $4.8M | $11.8M | $16.4M | $9.6M |
| Current Liabilities | $1.8M | $7.1M | $9.2M | $12.7M | $1.8M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.8M | $8.8M | $10.6M | $13.7M | $3.5M |
| Total Equity | -$1.3M | -$4.0M | $1.3M | $2.7M | $6.2M |
| Retained Earnings | -$2.8M | -$7.9M | -$24.4M | -$35.5M | -$54.2M |
Cash Flow (Annual)
Last updated: Jun 30, 2026 9:34pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M | -$4.1M | -$6.4M | -$11.9M | -$16.4M |
| Capital Expenditure | $0 | $0 | $-495,000 | $-184,000 | $-262,000 |
| Free Cash Flow | -$1.4M | -$4.1M | -$6.9M | -$12.1M | -$16.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $407,000 | $1.9M | $6.9M | $4.8M | -$9.1M |
Analyst Estimates (Annual)
Last updated: Jun 30, 2026 9:34pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 |
$7.5M $7.5M – $7.5M
|
$10.7M $10.7M – $10.7M
|
$19.2M $19.2M – $19.2M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$6.7M -$6.7M – -$6.7M
|
-$9.4M -$17.0M – -$1.8M
|
-$15.1M -$15.1M – -$15.1M
|
-$13.5M -$13.5M – -$13.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 30, 2026 9:34pm (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -183.1% | -99.0% | -54.5% | -21.2% |
| Net Income Growth | -223.7% | -221.9% | +32.3% | -67.1% |
| EBITDA Growth | -177.1% | -263.6% | +33.5% | -66.6% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-23 | Hoffman Robert E. | A-Award | 30,803.00 | $0.75 | $23,111 |
| 2026-06-23 | Cilento Richard C. Jr. | A-Award | 30,803.00 | $0.75 | $23,111 |
| 2026-06-23 | Link Matthew | A-Award | 30,803.00 | $0.75 | $23,111 |
| 2026-06-23 | Niklas Victoria Ninon Olivia | A-Award | 30,803.00 | $0.75 | $23,111 |
| 2026-05-04 | O'HEERON PETE | A-Award | 92,410.00 | $1.38 | $127,526 |
| 2026-05-04 | Khoja Hamid | A-Award | 61,607.00 | $1.38 | $85,018 |
| 2026-05-04 | Davis Jason | A-Award | 61,607.00 | $1.38 | $85,018 |
| 2026-05-04 | GARCIA RUBEN A | A-Award | 61,607.00 | $1.38 | $85,018 |
| 2026-03-04 | Khoja Hamid | P-Purchase | 30,000.00 | $0.38 | $11,400 |
| 2026-03-04 | O'HEERON PETE | P-Purchase | 15,872.00 | $0.38 | $6,006 |
| 2026-03-03 | O'HEERON PETE | P-Purchase | 18,200.00 | $0.41 | $7,373 |
| 2026-03-02 | O'HEERON PETE | P-Purchase | 17,428.00 | $0.35 | $6,152 |
| 2026-03-02 | Davis Jason | P-Purchase | 70,000.00 | $0.41 | $28,973 |
| 2026-02-27 | GARCIA RUBEN A | P-Purchase | 40,000.00 | $0.33 | $13,056 |
| 2025-12-11 | GARCIA RUBEN A | P-Purchase | 140,000.00 | $0.34 | $47,600 |
| 2025-06-12 | Niklas Victoria Ninon Olivia | A-Award | 22,000.00 | $0.87 | $19,195 |
| 2025-06-12 | Link Matthew | A-Award | 22,000.00 | $0.87 | $19,195 |
| 2025-06-12 | Hoffman Robert E. | A-Award | 22,000.00 | $0.87 | $19,195 |
| 2025-06-12 | Coen Stacy Ann | A-Award | 22,000.00 | $0.87 | $19,195 |
| 2025-06-12 | Cilento Richard C. Jr. | A-Award | 22,000.00 | $0.87 | $19,195 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for FBLG — it's generated by the pipeline (
market-narrative step).
No community reviews yet for FBLG.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.360 · 7b6df9be · 2026-06-30 17:24:24